Childhood psychiatric disorders

Children with ADHD or autism could be early indicator for younger siblings, new study finds

Retrieved on: 
Monday, December 10, 2018
Psychiatry, Psychiatric diagnosis, Abnormal psychology, Neuroscience, Learning disabilities, Attention deficit hyperactivity disorder, Childhood psychiatric disorders, Autism, Autism spectrum, Attention deficit hyperactivity disorder controversies, Heritability of autism

According to the findings, younger brothers and sisters of children with ADHD are 13 times more likely to develop ADHD and 4 times more likely to be on the autism spectrum.

Key Points: 
  • According to the findings, younger brothers and sisters of children with ADHD are 13 times more likely to develop ADHD and 4 times more likely to be on the autism spectrum.
  • For children with autism, the likelihood that younger siblings could receive an ADHD diagnosis is 3.5 times higher.
  • This is the first time the recurrence of ADHD has been examined in younger brothers and sisters of children who have been diagnosed with either ADHD or autism, according to Erica Musser , FIU psychologist and study co-author.
  • With this data, researchers were able to determine younger siblings of children with ADHD are at greater risk of developing either ADHD or autism.

Aevi Genomic Medicine to Host KOL Breakfast to Discuss Diagnosis and Treatment Paradigms in ADHD

Retrieved on: 
Monday, November 26, 2018
Psychiatry, Childhood psychiatric disorders, Psychiatric diagnosis, Child and adolescent psychiatry, Attention deficit hyperactivity disorder, Health, Abnormal psychology

PHILADELPHIA, Nov. 26, 2018 /PRNewswire/ --Aevi Genomic Medicine, Inc.(NASDAQ: GNMX) (the Company) announced today that the Aevi Genomic Medicine Management team will host a breakfast with Key Opinion Leader (KOL) Robert Findling, M.D., Leonard and Helen R. Stulman Professor in Child and Adolescent Psychiatry at Johns Hopkins University.

Key Points: 
  • PHILADELPHIA, Nov. 26, 2018 /PRNewswire/ --Aevi Genomic Medicine, Inc.(NASDAQ: GNMX) (the Company) announced today that the Aevi Genomic Medicine Management team will host a breakfast with Key Opinion Leader (KOL) Robert Findling, M.D., Leonard and Helen R. Stulman Professor in Child and Adolescent Psychiatry at Johns Hopkins University.
  • During the breakfast they will discuss the diagnosis and treatment paradigms in Attention Deficit Hyperactivity Disorder (ADHD).
  • The breakfast is being held on Thursday, November 29, 2019 at 8:00 AM EST at the National in New York, New York.
  • As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.

The global disruptive behavior disorder treatment market size is expected to reach USD 24.0 billion by 2026

Retrieved on: 
Wednesday, November 14, 2018
Psychiatry, Psychiatric diagnosis, Childhood psychiatric disorders, Psychology, Behavioural sciences, Abnormal psychology, Conduct disorder, Psychopathy, Disruptive Behavior Disorders Rating Scale, Oppositional defiant disorder

NEW YORK, Nov. 14, 2018 /PRNewswire/ -- Disruptive Behavior Disorder (DBD) Treatment Market Size, Share & Trends Analysis Report By Type (Oppositional Defiant, Conduct), By Treatment (Parenting, Individual), By Region, And Segment Forecasts, 2018 - 2026

Key Points: 
  • NEW YORK, Nov. 14, 2018 /PRNewswire/ -- Disruptive Behavior Disorder (DBD) Treatment Market Size, Share & Trends Analysis Report By Type (Oppositional Defiant, Conduct), By Treatment (Parenting, Individual), By Region, And Segment Forecasts, 2018 - 2026
    The global disruptive behavior disorder treatment market size is expected to reach USD 24.0 billion by 2026, according to a new report by Grand View Research, Inc.
  • Increasing cases of substance abuse across the globe are considered to be the key factors driving the market.
  • Drug abuse is one of the major causes for acquiring oppositional defiant and conduct disorder as it enhances the symptoms for such conditions.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Tris Pharma Presents Clinical Data for DYANAVEL® XR (amphetamine) at the 2018 Neuroscience Education Institute (NEI) Congress

Retrieved on: 
Monday, November 12, 2018
Psychiatry, Attention deficit hyperactivity disorder, Childhood psychiatric disorders, Amphetamine, Neuroscience, Educational psychology, Psychiatric diagnosis, Health, Attention deficit hyperactivity disorder controversies, Attention deficit hyperactivity disorder management

DYANAVEL XR is approved to treat children six years and older with Attention Deficit/Hyperactivity Disorder (ADHD).

Key Points: 
  • DYANAVEL XR is approved to treat children six years and older with Attention Deficit/Hyperactivity Disorder (ADHD).
  • "Tris is committed to providing differentiated pediatric-friendly treatment options for children with ADHD," said Ketan Mehta, President and Chief Executive Officer of Tris.
  • Data from studies presented at the NEI Congress provide further insight into the role DYANAVEL XR could play in the clinical management of patients with ADHD."
  • Tris Pharma is a fully integrated pharmaceutical company focused on the development of innovative medicines that address unmet patient needs.

Global Attention Deficit Hyperactivity Disorder Market and Competitive Landscape 2014-2023: Pipeline, Epidemiology, Market Valuations, Product Sales, Market Forecast, Product Forecasts, and Market Shares

Retrieved on: 
Tuesday, October 9, 2018
Psychiatry, Childhood psychiatric disorders, Attention deficit hyperactivity disorder, Educational psychology, Psychiatric diagnosis, Health, Neuroscience, Amphetamine, Attention deficit, Déficit, Attention deficit hyperactivity disorder controversies, Adult attention deficit hyperactivity disorder

The "Global Attention Deficit Hyperactivity Disorder Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Attention Deficit Hyperactivity Disorder Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Attention Deficit Hyperactivity Disorder Market and Competitive Landscape - 2018, provides comprehensive insights into Attention Deficit Hyperactivity Disorder pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • The research is classified into following sections - Attention Deficit Hyperactivity Disorder overview with definitions, symptoms, etiology, diagnosis, treatment options; Attention Deficit Hyperactivity Disorder pipeline insights covering late stage clinical trials pipeline; Attention Deficit Hyperactivity Disorder prevalence trends by countries; Attention Deficit Hyperactivity Disorder market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.
  • Attention Deficit Hyperactivity Disorder pipeline: Find out the drugs in clinical trials for Attention Deficit Hyperactivity Disorder by stages, phase 3 clinical trials, phase 2 clinical trials, and phase 1 clinical trials, by pharmacological class, by company
    Attention Deficit Hyperactivity Disorder epidemiology: Find out the prevalence of Attention Deficit Hyperactivity Disorder by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; prevalence forecast to 2023
    Attention Deficit Hyperactivity Disorder products: Identify key products marketed and prescribed for Attention Deficit Hyperactivity Disorder by brand name, by molecule, by company, by branded / generic, by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Attention Deficit Hyperactivity Disorder market size: Find out the market size for Attention Deficit Hyperactivity Disorder drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; Find out how the market advanced from 2014
    Attention Deficit Hyperactivity Disorder drug sales: Find out the sales of Attention Deficit Hyperactivity Disorder drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan, Global
    Attention Deficit Hyperactivity Disorder drugs sales forecast: Sales forecast for Attention Deficit Hyperactivity Disorder drugs to 2023 by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Attention Deficit Hyperactivity Disorder market share analysis: Find out the market shares of Attention Deficit Hyperactivity Disorder drugs and outlook by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Did you know that we also offer Custom Research?

Patrick McKenna and Other Canadian Celebrities Speak out About ADHD and Invite the Public to Join the Conversation #ADHD Speaks

Retrieved on: 
Tuesday, October 2, 2018
Information science, Psychiatry, Information retrieval, Childhood psychiatric disorders, Educational psychology, Rick Green, Attention deficit hyperactivity disorder, Hashtag, Selfie

People all across the country are invited to submit selfie videos and use the campaign hashtag, #ADHDspeaks, to join the conversation.

Key Points: 
  • People all across the country are invited to submit selfie videos and use the campaign hashtag, #ADHDspeaks, to join the conversation.
  • There is still so much misinformation and judgment out there about ADHD which just continues to fuel the existing stigma.
  • Canadian celebrities Patrick McKenna, Tazz Norris, Rick Green, Simon Rakoff, and Zoe Kessler have already sent in individual videos, sharing their personal experiences with ADHD.
  • CADDAC, Centre for ADHD Awareness Canada, is a national not-for-profit organization providing leadership in awareness, education and advocacy for ADHD organizations and individuals with ADHD across Canada.

"Relationship ADHD": Have We Lost the Instinct for Commitment?

Retrieved on: 
Friday, September 28, 2018
Psychiatry, Childhood psychiatric disorders, Educational psychology, Amphetamine, Attention deficit hyperactivity disorder, Methylphenidate, Psychiatric diagnosis, Health, Abnormal psychology

Yet it seems that the ways in which relationships develop or fail to develop have changed.

Key Points: 
  • Yet it seems that the ways in which relationships develop or fail to develop have changed.
  • When a new date can be found with a swipe, why take the time to let a real relationship develop?
  • In this or any other time, the only way to avoid 'relationship ADHD' is through open and honest communication."
  • (*) Stanley, S. M., Rhoades, G. K., Scott, S. B., Kelmer, G., Markman, H. J., & Fincham, F. D. Asymmetrically committed relationships.

DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization for ADHD in Taiwan

Retrieved on: 
Tuesday, September 18, 2018
Neuroscience, Neurochemistry, Chemistry, Amphetamine, Euphoriants, Nootropics, Methylphenidate, Childhood psychiatric disorders, Attention deficit hyperactivity disorder

Methydur Sustained Release Capsules are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and will be available in three strengths (22 mg, 33 mg and 44 mg) in Taiwan.

Key Points: 
  • Methydur Sustained Release Capsules are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and will be available in three strengths (22 mg, 33 mg and 44 mg) in Taiwan.
  • Orient Pharma's safety analysis indicates that the incidence of adverse events with Methydur Sustained Release Capsules was similar to other approved Methylphenidate products.
  • If commercialized, DURECT will be entitled to receive a royalty on sales of Methydur Sustained Release Capsules by Orient Pharma.
  • Orient Pharma has also committed to supply a portion of the commercial requirements in territories other than the United States for Methydur Sustained Release Capsules.

Researchers Find Children Experience Concussion Symptoms Three Times Longer Than Adults

Retrieved on: 
Monday, September 17, 2018
Psychiatric diagnosis, Psychiatry, RTT, Medicine, Medical diagnosis, Neurotrauma, Mood disorders, Childhood psychiatric disorders, Major depressive disorder, Concussion, Anxiety, Attention deficit hyperactivity disorder

Kids were told to stay home from school and sit in a dark room for two weeks," says Dr. Zwibel.

Key Points: 
  • Kids were told to stay home from school and sit in a dark room for two weeks," says Dr. Zwibel.
  • The article also cites children's vulnerability to prolonged symptoms due to underlying conditions, including ADHD, depression, anxiety and stress.
  • Researchers say rehabilitation has also proven effective for mitigating symptoms such as dizziness and changes in vision, like difficulty with focus.
  • While active recovery has emerged as the standard of treatment, Dr. Zwibel says athletes should not compete while they are experiencing concussion symptoms.

Doctors Develop the Ability to Diagnose Patients With ADHD Online

Retrieved on: 
Thursday, September 6, 2018
Psychiatry, Attention deficit hyperactivity disorder, Childhood psychiatric disorders, Neuroscience, Educational psychology, Cognition, Amphetamine, Psychiatric diagnosis, Attention deficit hyperactivity disorder controversies

GRAND RAPIDS, Mich., Sept. 6, 2018 /PRNewswire/ -- ADHD Diagnosis Online isrevolutionizing the field of ADHD.

Key Points: 
  • GRAND RAPIDS, Mich., Sept. 6, 2018 /PRNewswire/ -- ADHD Diagnosis Online isrevolutionizing the field of ADHD.
  • "Patients who are struggling with ADHD often suffer from anxiety and depression as they feel their lives spiraling out of control."
  • "We are the first and only online ADHD Diagnosis company in America,"commented Zachariah Booker, ADHD Philanthropist, and owner of ADHD Diagnosis Online.
  • With ADHD being present in an estimated 5% of children and 2.5% of adults, ADHD Diagnosis Online is guaranteed to be revolutionary.